AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?
The 2022 American Urological Association (AUA) Annual Meeting included a [...]
Quality of life on lenvatinib plus pembrolizumab combination
In this study, the health-related quality of life (HRQoL) of [...]
Treatment of people who relapse on adjuvant pembrolizumab
Adjuvant treatment is treatment that is given after surgery to [...]
ASCO GU 2022: Pembrolizumab as adjuvant therapy for kidney cancer
Nephrectomy is the standard of care for advanced renal cell [...]
Stereotactic radiotherapy and pembrolizumab for kidney cancer
Results from the phase 1/2 RAPPORT trial show that stereotactic [...]
Adjuvant pembrolizumab gets positive opinion from the European CHMP
We have just learnt that the Committee for Medicinal Products [...]
FDA approves adjuvant pembrolizumab for intermediate-high risk kidney cancer
The Food and Drug administration (FDA) in the USA has [...]
Risks and benefits of adjuvant therapy for kidney cancer
Treatment of people with intermediate to high risk renal cell [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer
Non-clear cell RCC is about 20-25% of all RCC diagnoses [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer
KEYNOTE-427 is an open-label, single-arm, phase II study to look [...]
